These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20636022)

  • 21. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
    Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leishmaniasis: Immunological and clinical aspects and vaccines in Venezuela.
    Convit J
    Clin Dermatol; 1996; 14(5):479-87. PubMed ID: 8889325
    [No Abstract]   [Full Text] [Related]  

  • 23. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure.
    Coutinho SG; Oliveira MP; Da-Cruz AM; De Luca PM; Mendonça SC; Bertho AL; Soong L; McMahon-Pratt D
    Exp Parasitol; 1996 Nov; 84(2):144-55. PubMed ID: 8932764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
    Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in Brazil.
    Monjour L; Neogy AB; Vouldoukis I; Silva OA; Boisnic S; Brito ME; Lesot A; Vignot N; Martins JS; Jardim ML
    Mem Inst Oswaldo Cruz; 1994; 89(3):479-83. PubMed ID: 7476236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leishmania major MAP kinase 10 is protective against experimental L. major infection.
    Kumari S; Singh S; Saha B; Paliwal PK
    Vaccine; 2011 Nov; 29(48):8783-7. PubMed ID: 21527301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemokines in host-parasite interactions in leishmaniasis.
    Teixeira MJ; Teixeira CR; Andrade BB; Barral-Netto M; Barral A
    Trends Parasitol; 2006 Jan; 22(1):32-40. PubMed ID: 16310413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?
    McMahon-Pratt D; Alexander J
    Immunol Rev; 2004 Oct; 201():206-24. PubMed ID: 15361243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.
    Roatt BM; Aguiar-Soares RD; Coura-Vital W; Ker HG; Moreira Nd; Vitoriano-Souza J; Giunchetti RC; Carneiro CM; Reis AB
    Front Immunol; 2014; 5():272. PubMed ID: 24982655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
    Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
    J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological correlates of cure in the first American cutaneous leishmaniasis patient treated by immunotherapy in Argentina. A case report.
    García Bustos MF; Barrio AB; Parodi Ramoneda CM; Ramos F; Mora MC; Convit J; Basombrío MA
    Invest Clin; 2011 Dec; 52(4):365-75. PubMed ID: 22523846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis.
    Kaye PM; Curry AJ; Blackwell JM
    J Immunol; 1991 Apr; 146(8):2763-70. PubMed ID: 1901883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y; Jones DE
    Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.